Aurélie Mougel

Aurélie Mougel

Auto-generated profile, based on publicly available information

Aurélie Mougel

Neovacs SA, 92150 Suresnes, France

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 December 2025 in Science Translational Medicine
Verified
Journal Article
Closed access
ECEva Conde
Eva Conde
ELEmma Lamanna
Emma Lamanna
AMAurélie Mougel
Aurélie Mougel
JKJasper Kamphuis
Jasper Kamphuis
ALAlexia Loste
Alexia Loste
LRLaurent L. Reber
Laurent L. Reber
Immunoglobulin E (IgE) antibodies play a key role in allergy and its most dangerous and life-threatening manifestation, anaphylaxis. Anti-IgE monoclonal antibodies (mAbs) have been developed to treat IgE-dependent diseases such as allergic asthma, food allergy, and chronic spontaneous urticaria. However, their use is still restricted to a minority of patients suffering from the most severe symptoms because treatment is costly and requires repeated administration. Therefore, we developed a conjugate vaccine against human IgE as a potential alternative therapy for long-term protection from IgE-dependent diseases. The IgE conjugate vaccine was generated by coupling a mutated fragment containing the Cε3-4 domains of human IgE with the carrier protein diphtheria cross-reactive material 197 (CRM 197 ) using kinoid technology to raise autoantibodies against a self-antigen by engrafting it onto the highly immunogenic CRM 197 carrier. To assess the efficacy of IgE-kinoid (IgE-K) vaccination, we generated a mouse model humanized for IgE and its high-affinity receptor FcεRI. IgE-K vaccination induced long-term production of anti–human IgE neutralizing antibodies without any detectable adverse effect. Anti-IgE antibodies were detected in the sera of IgE-K–immunized mice for up to 12 months postvaccination with a similar avidity as the approved anti-IgE mAb omalizumab. Furthermore, IgE-K vaccination protected against both IgE-mediated cutaneous and severe systemic anaphylaxis in IgE/FcεRI-humanized mice. Our results demonstrate that long-term reduction in IgE activity can be achieved through vaccination with human kinoids and can protect against anaphylaxis in humanized mice. This may represent a cost-effective, long-term therapeutic strategy for the treatment of IgE-mediated diseases.

9 April 2021 in Science
Verified
Journal Article
Closed access
PDF file
JKJasper Kamphuis
Jasper Kamphuis
WWWilliam P. M. Worrall
William P. M. Worrall
JSJulien Stackowicz
Julien Stackowicz
AMAurélie Mougel
Aurélie Mougel
EMEmilie Mauré
Emilie Mauré
LRLaurent L. Reber
Laurent L. Reber
Taniguchi et al . (Research Articles, 17 July 2020, p. 269) claim that the cytokine interleukin-33 induces accumulation of tumor-associated macrophages expressing the immunoglobulin E receptor FcεRI. Although these findings hold great therapeutic promise, we provide evidence that the anti-FcεRI antibody used in this study is not specific for FcεRI on macrophages, which raises concerns about the validity of some of the conclusions.

21 October 2025 in Allergy
Verified
Journal Article
Open access
AMAurélie Mougel
Aurélie Mougel
KLKatia Lemdani
Katia Lemdani
NSNadine Serhan
Nadine Serhan
CHCharlotte Hateb
Charlotte Hateb
JBJonathan Bonnefoy
Jonathan Bonnefoy
LRLaurent L. Reber
Laurent L. Reber